rs200750137
Positions:
Variant summary
Our verdict is Benign. Variant got -15 ACMG points: 0P and 15B. BP4_StrongBP6_ModerateBP7BS1BS2
The NM_005210.4(CRYGB):āc.312A>Gā(p.Ser104Ser) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00155 in 1,614,066 control chromosomes in the GnomAD database, including 73 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ).
Frequency
Genomes: š 0.00077 ( 2 hom., cov: 33)
Exomes š: 0.0016 ( 71 hom. )
Consequence
CRYGB
NM_005210.4 synonymous
NM_005210.4 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.832
Genes affected
CRYGB (HGNC:2409): (crystallin gamma B) Crystallins are separated into two classes: taxon-specific, or enzyme, and ubiquitous. The latter class constitutes the major proteins of vertebrate eye lens and maintains the transparency and refractive index of the lens. Since lens central fiber cells lose their nuclei during development, these crystallins are made and then retained throughout life, making them extremely stable proteins. Mammalian lens crystallins are divided into alpha, beta, and gamma families; beta and gamma crystallins are also considered as a superfamily. Alpha and beta families are further divided into acidic and basic groups. Seven protein regions exist in crystallins: four homologous motifs, a connecting peptide, and N- and C-terminal extensions. Gamma-crystallins are a homogeneous group of highly symmetrical, monomeric proteins typically lacking connecting peptides and terminal extensions. They are differentially regulated after early development. Four gamma-crystallin genes (gamma-A through gamma-D) and three pseudogenes (gamma-E, gamma-F, gamma-G) are tandemly organized in a genomic segment as a gene cluster. Whether due to aging or mutations in specific genes, gamma-crystallins have been involved in cataract formation. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -15 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.64).
BP6
Variant 2-208142854-T-C is Benign according to our data. Variant chr2-208142854-T-C is described in ClinVar as [Benign]. Clinvar id is 474172.Status of the report is criteria_provided_single_submitter, 1 stars. Variant chr2-208142854-T-C is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-0.832 with no splicing effect.
BS1
Variant frequency is greater than expected in population sas. gnomad4 allele frequency = 0.000768 (117/152338) while in subpopulation SAS AF= 0.024 (116/4832). AF 95% confidence interval is 0.0205. There are 2 homozygotes in gnomad4. There are 100 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck.
BS2
High AC in GnomAd4 at 117 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CRYGB | NM_005210.4 | c.312A>G | p.Ser104Ser | synonymous_variant | 3/3 | ENST00000260988.5 | NP_005201.2 | |
CRYGB | XM_017003402.2 | c.318A>G | p.Ser106Ser | synonymous_variant | 3/3 | XP_016858891.1 | ||
LOC100507443 | NR_038437.1 | n.221+5675T>C | intron_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CRYGB | ENST00000260988.5 | c.312A>G | p.Ser104Ser | synonymous_variant | 3/3 | 1 | NM_005210.4 | ENSP00000260988.4 |
Frequencies
GnomAD3 genomes AF: 0.000775 AC: 118AN: 152220Hom.: 2 Cov.: 33
GnomAD3 genomes
AF:
AC:
118
AN:
152220
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00344 AC: 859AN: 250026Hom.: 26 AF XY: 0.00475 AC XY: 642AN XY: 135166
GnomAD3 exomes
AF:
AC:
859
AN:
250026
Hom.:
AF XY:
AC XY:
642
AN XY:
135166
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00163 AC: 2380AN: 1461728Hom.: 71 Cov.: 33 AF XY: 0.00245 AC XY: 1782AN XY: 727166
GnomAD4 exome
AF:
AC:
2380
AN:
1461728
Hom.:
Cov.:
33
AF XY:
AC XY:
1782
AN XY:
727166
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000768 AC: 117AN: 152338Hom.: 2 Cov.: 33 AF XY: 0.00134 AC XY: 100AN XY: 74502
GnomAD4 genome
AF:
AC:
117
AN:
152338
Hom.:
Cov.:
33
AF XY:
AC XY:
100
AN XY:
74502
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
20
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
CRYGB-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 05, 2019 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Cataract 39 multiple types Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 27, 2023 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at